Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06371157
PHASE3

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Sponsor: Akeso

View on ClinicalTrials.gov

Summary

A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma

Official title: A Phase III, Randomized, Double-blinded, Multicenter Study of Cadonilimab (AK104) + Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

469

Start Date

2024-08-02

Completion Date

2026-05-23

Last Updated

2025-03-12

Healthy Volunteers

No

Interventions

DRUG

AK104

intravenous

DRUG

Lenvatinib

oral

PROCEDURE

TACE

TACE (chemo and embolic agent injection into the hepatic artery)

OTHER

Placebo for AK104

intravenous

OTHER

Placebo for Lenvatinib

oral

Locations (4)

Henan Cancer Hospital

Zhengzhou, Henan, China

Hunan Cancer Hospital

Changsha, Hunan, China

Zhongda Hospital Southeast University

Nanjing, Jiangsu, China

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China